1. A 24‐Week, Randomized, Controlled Trial of Rivastigmine Patch 13.3 mg/24 h Versus 4.6 mg/24 h in Severe Alzheimer's Dementia. (7th August 2013) Authors: Farlow, Martin R.; Grossberg, George T.; Sadowsky, Carl H.; Meng, Xiangyi; Somogyi, Monique Journal: CNS neuroscience & therapeutics Issue: Volume 19:Number 10(2013) Page Start: 745 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Efficacy of higher‐dose 13.3 mg/24 h (15 cm2) rivastigmine patch on the Alzheimer's Disease Assessment Scale–cognitive subscale: domain and individual item analysis. (18th February 2014) Authors: Alva, Gustavo; Isaacson, Richard; Sadowsky, Carl; Grossberg, George; Meng, Xiangyi; Somogyi, Monique Journal: International journal of geriatric psychiatry Issue: Volume 29:Number 9(2014:Sep.) Page Start: 920 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P3–268: Effect of body mass index on the efficacy, safety and tolerability of a higher‐dose 13.3 mg/24 h rivastigmine patch in people with severe Alzheimer's disease. (1st July 2013) Authors: Sadowsky, Carl; Somogyi, Monique; Frolich, Lutz; Meng, Xiangyi Journal: Alzheimer's & dementia Issue: Volume 9:Supplement 4S(2013)Part 16 Page Start: P654 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. P3–270: A 24‐week, open‐label extension to the ACTivities of daily living and cognitION (ACTION) study: Long‐term safety, tolerability and efficacy of a 13.3 mg/24 h rivastigmine patch in people with severe Alzheimer's disease. (1st July 2013) Authors: Farlow, Martin; Grossberg, George; Sadowsky, Carl; Meng, Xiangyi; Somogyi, Monique Journal: Alzheimer's & dementia Issue: Volume 9:Supplement 4S(2013)Part 16 Page Start: P655 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. P3–273: Efficacy, safety and tolerability of a higher‐dose 13.3 mg/24 h rivastigmine patch in people with severe Alzheimer's disease with and without concomitant memantine use. (1st July 2013) Authors: Grossberg, George; Farlow, Martin; Meng, Xiangyi; Somogyi, Monique Journal: Alzheimer's & dementia Issue: Volume 9:Supplement 4S(2013)Part 16 Page Start: P656 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. P3–299: Infrequent skin reactions at the application site of the rivastigmine patch (4.6, 9.5 or 13.3 mg/24 h): Analysis of two clinical studies revealed most were tolerable and manageable across all doses. (1st July 2013) Authors: Alva, Gustavo; Cummings, Jeffrey; Galvin, James; Meng, Xiangyi; Somogyi, Monique Journal: Alzheimer's & dementia Issue: Volume 9:Supplement 4S(2013)Part 17 Page Start: P666 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗